Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations

Trojaniello, C; Festino, L; Vanella, V; Ascierto, PA

Ascierto, PA (reprint author), Ist Nazl Tumori IRCCS Fdn G Pascale, Unit Melanoma, Canc Immunotherapy & Dev Therapeut, Via Mariano Semmola Snc, Naples, Italy.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019; 12 (3): 259

Abstract

Introduction: Combination treatment with a BRAF inhibitor and MEK inhibitor is the standard of care for patients with advanced BRAF(V600) mutation-pos......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索